Sanofi's Potential Rare Disease Treatment Meets All Endpoints in Phase 3 Study

MT Newswires Live06-30 17:27

Sanofi's (SNY) Nexviazyme met all primary and secondary endpoints as a potential treatment for infantile-onset Pompe disease in a phase 3 study, the company said.

Pompe disease is a rare ailment with symptoms that include skeletal muscle weakness causing mobility problems and impacting the respiratory system.

The drug met its primary endpoint of keeping patients alive and free of invasive ventilation in previously untreated infants at 52 weeks, the company said.

The study met all secondary endpoints, including proportion of participants alive and free of invasive ventilation at 12 and 18 months of age, and improvements in other measures of disease progression at 52 weeks, the company said.

Sanofi plans to submit the data to support a US regulatory application in H2 2026, the company said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment